MaxCyte Inc (MXCT) Ord USD0.01 (DI)
MaxCyte, Inc. focuses on cell-based medicines. The Company provide high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. The Company’s platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. The Company is developing CARMA, its platform in immuno-oncology, to rapidly manufacture chimeric antigen receptor (CAR) therapies for a broad range of cancer indications, including solid tumors where existing chimeric antigen receptor T cell (CAR-T) approaches face challenges. The Company's products include instruments, processing assemblies and insourcing services. The Company's instruments include systems, such as the MaxCyte STX, the MaxCyte VLX and the MaxCyte GT.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.